Sol-Gel Technologies EBIT 2016-2024 | SLGL

Sol-Gel Technologies ebit from 2016 to 2024. Ebit can be defined as earnings before interest and taxes.
Sol-Gel Technologies Annual EBIT
(Millions of US $)
2023 $-29
2022 $-16
2021 $3
2020 $-30
2019 $-26
2018 $-34
2017 $-32
2016 $-21
2015 $-10
Sol-Gel Technologies Quarterly EBIT
(Millions of US $)
2024-06-30 $2
2024-03-31 $-7
2023-12-31 $-5
2023-09-30 $-6
2023-06-30 $-7
2023-03-31 $-11
2022-12-31 $-6
2022-09-30 $-4
2022-06-30 $-0
2022-03-31 $-6
2021-12-31 $14
2021-09-30 $1
2021-06-30 $-8
2021-03-31 $-4
2020-12-31 $-7
2020-09-30 $-9
2020-06-30 $-8
2020-03-31 $-7
2019-12-31 $-7
2019-09-30 $-8
2019-06-30 $-5
2019-03-31 $-6
2018-12-31 $-12
2018-09-30 $-8
2018-06-30 $-7
2018-03-31 $-6
2017-12-31
2017-09-30
2017-06-30 $-6
2016-12-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.015B $0.002B
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00